Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Columvi Shows High Response Rates and Safety in R/R Mantle Cell Lymphoma

November 19th 2024, 2:00pm

Article

Treatment with Columvi showed a manageable safety profile in heavily pre-treated patients with relapsed or refractory mantle cell lymphoma.

Boruzu Approved by FDA For Multiple Myeloma, Mantle Cell Lymphoma

September 6th 2024, 1:48pm

Article

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma.

CAR-T Cell Therapy for Relapsed, Refractory Mantle Cell Lymphoma Fills Unmet Need

July 24th 2024, 9:00pm

Article

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.

Finding a Second Opinion Was a Pivotal Moment in My Cancer Experience

July 18th 2024, 1:00pm

Article

From second opinions to research and asking for help, here are some pivotal lessons I learned after a mantle cell lymphoma diagnosis.

FDA Approves Breyanzi for Relapsed, Refractory MCL

May 30th 2024, 4:42pm

Article

The CAR-T cell therapy, Breyanzi, has received FDA approval for relapsed or refractory mantle cell lymphoma.

Calquence Regimen Improves Outcomes in Frontline Mantle Cell Lymphoma

May 2nd 2024, 9:00pm

Article

Adding Calquence to standard-of-care chemoimmunotherapy improved progression-free survival in patients with previously untreated mantle cell lymphoma.

Cord Blood-Derived Treatment Shows Promise in Blood Cancer

January 25th 2024, 8:00pm

Article

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

‘Remarkable’ Results from Tecartus in Patients With R/R MCL

January 4th 2024, 10:00pm

Article

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

Tecartus Induces Responses in Real-World Population of High-Risk R/R MCL

December 10th 2023, 12:25am

Article

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Encouraging Trial Results Announced for Breyanzi in Lymphoma Treatment

May 17th 2023, 9:00pm

Article

Breyanzi has reportedly shown promising effects for patients with relapsed or refractory follicular lymphoma and B-cell non-Hodgkin lymphoma.